12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GDC-0068: Phase Ib data

An open-label, dose-escalation, international Phase Ib trial in 23 patients with advanced or metastatic solid tumors showed that 100, 200 and 400 mg doses of daily GDC-0068 plus docetaxel and 100 and 200 mg doses of daily GDC-0068 plus FOLFOX6 (5-FU, leucovorin, and oxaliplatin)...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >